IV ITRACONAZOLE VS AMPHOTERICIN B IN BLASTOMYCOSIS OR HISTOPLASMOSIS

本研究的主要目的是评估IV 伊曲康唑与标准治疗（两性霉素B）相比。 研究 还将评估临床、微生物学和总体反应， IV诱导治疗结束时（7-14天）和PO后的治疗 在第2、12和24周进行巩固治疗。 患者将被随机分配至IV 伊曲康唑每日两次，持续两天（负荷剂量），然后每日一次 再给药5天，或用阿替西菌素-B IV给药7天。 扩展 如果病人的临床情况需要， 了 IV治疗后将进行巩固治疗， 伊曲康唑胶囊，每日一次或每日两次，持续一年。 在诱导治疗期间（7-14天）， 一个小时的时间。 IV两性霉素B在1-6小时内输注 这取决于患者对治疗的副作用。 期间 巩固治疗口服伊曲康唑，每日一次，或 一天两次，持续一年。

The primary purpose of this study is to assess the safety of IV itraconazole compared to the standard of care (Amphotericin B). The study will also assess the clinical, microbiological, and overall response to therapy at the end of IV induction therapy (7-14 days) and after PO consolidation therapy at 2, 12, and 24 weeks. Patients will be randomized to either an initial treatment with IV itraconazole twice a day for two days (loading dose) and then once a day for five additional days or amphotericin-B IV for seven days. Extended treatment would be allowed if the patient's clinical condition required it. IV treatment will be followed by consolidation therapy with itraconazole capsules once daily or twice a day for up to one year. During induction therapy (7-14 days) IV itraconazole is infused over a one-hour period of time. IV Amphotericin-B is infused over a 1-6 hour period of time depending on the patient's side effects to therapy. During consolidation therapy oral itraconazole is given either once a day or twice a day for up to one year.